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Abstract
Background: The demonstration of EGFR T790M gene mutation in plasma is crucial to assess the eligibility of Non
Small Cell Lung Cancer (NSCLC) patients, who have acquired resistance to first or second generation Tyrosine
Kinase Inhibitors (TKIs), to receive a subsequent treatment with osimertinib. Since circulating tumor DNA (ctDNA) is
present in very low amounts in plasma, high sensitive and specific methods are required for molecular analysis.
Improving sensitivity of T790M mutation detection in plasma ctDNA enables a larger number of NSCLC patients to
receive the appropriate therapy without any further invasive procedure.
Methods: A tag-based next generation sequencing (NGS) platform capable of tagging rare circulating tumor DNA
alleles was employed in this study for the identification of T790M mutation in 42 post-TKI NSCLC patients.
Results: Compared to Real Time PCR, tag-based NGS improved the T790M detection rate (42.85% versus 21.4%,
respectively), especially in those cases with a low median mutation abundance (i.e. 0.24, range 0.07–0.78). Moreover,
the tag-based NGS identified EGFR activating mutations more efficiently than Real Time PCR (85.7% versus 61.9%
detection rate, respectively), particularly of the L858R variant type (0.06–0.75 mutation abundance range). Patients in
whom the T790M mutation was detected in plasma, achieved an objective response to osimertinib (9/14, 64.28%).
Conclusions: Tag-based NGS represents an accurate and sensitive tool in a clinical setting for non-invasive
assessment and monitoring of T790M variant in NSCLC patients.
Keywords: Circulating tumor DNA, Liquid biopsy, NSCLC, EGFR TKIs, T790M resistance mutation, Molecular tag, Next
generation sequencing, C797S
Background
The current standard work-up of Non Small Cell Lung
Cancer (NSCLC) patients includes the search for sensi-
tizing mutations of EGFR gene (Sharma et al. 2007; Riely
et al. 2006; Rosell et al. 2010; Mok et al. 2009) that
allowed identification of patients eligible for treatment
with an EGFR tyrosine kinase inhibitor (TKI) (Singh &
Jadhav 2018). Most patients respond to first and
second-generation EGFR TKIs, such as gefitinib, erloti-
nib and afatinib, but acquired resistance is likely to
occur, leading to disease progression. EGFR T790M sub-
stitution has been indicated as the prevalent molecular
event involved and occurs in approximately 50–60% of
the cases developing TKI resistance (Yu et al. 2013; Hata
et al. 2013; Sequist et al. 2011; Oxnard et al. 2011; Cross
et al. 2014). Osimertinib is a third-generation EGFR
TKI, designed to overcome resistance due to T790M
and representing the current standard treatment for
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advanced, T790M-positive NSCLC patients progressing
after first or second- generation EGFR TKI (Cross et al.
2014; Ramalingam et al. 2018). However, more recently
the U.S. Food and Drug Administration (FDA) has ap-
proved the use of osimertinib also in first line for ad-
vanced NSCLC harboring common EGFR mutations
(Mok et al. 2017).
Although T790M can be identified through a new bi-
opsy of the progressing neoplasm, this procedure may
be challenging as well as stressful for the patient, and
could potentially lead to complications. Several studies
have demonstrated the feasibility of assessing EGFR mu-
tational status on circulating cell-free DNA (cfDNA)
from plasma (Douillard et al. 2014; Sorensen et al. 2014;
Sundaresan et al. 2016; Vanni et al. 2015). The cfDNA is
becoming a reliable alternative source to tumor DNA,
although the sensitivity of methods using cfDNA is gen-
erally lower (Ramalingam et al. 2018; Vanni et al. 2015;
Luo et al. 2014; Oxnard et al. 2016). This approach is
non-invasive, does not pose limitations to repeated sam-
pling, and provides a sufficiently accurate assessment of
intra and inter-tumor heterogeneity (Sundaresan et al.
2016; Murtaza et al. 2013; Diaz and Bardelli, 2014). Be-
cause circulating cell-free tumor-derived DNA (ctDNA)
is diluted out with normal DNA, ctDNA analysis is tech-
nically challenging requiring both sensitivity and accur-
acy (Murtaza et al. 2013). The current methods for the
detection of plasma T790M in clinical practice include
digital PCR (dPCR) techniques, Real Time PCR assays
and Next Generation Sequencing (NGS) (Thress et al.,
2015a; Bartels et al. 2017; Kim et al. 2013;
Mayo-de-las-Casas et al. 2017). Variable T790M detec-
tion rates have been reported ranging between 31 and
66% for BEAMing (beads, emulsion, amplification and
magnetics) digital PCR; 18–52% for droplet digital PCR
(ddPCR) and 22–30% for common Real Time PCR as-
says (Luo et al. 2014; Mayo-de-las-Casas et al. 2017). Im-
proving the reliability of T790M detection in cfDNA
would represent a significant achievement, as it would
permit the access to an effective therapeutic agent to a
larger number of patients in the absence of repeated tis-
sue biopsies. Here, we have studied a commercial NGS
panel using molecular tagging of the DNA alleles
present in the plasma, and compared the results ob-
tained with those by Real Time PCR.
Material and methods
Patients
Plasma samples of 42 patients with NSCLC were col-
lected between 2016 and 2018. This cohort included pa-
tients with a histologic diagnosis of advanced NSCLC
harboring sensitizing EGFR mutations, who experienced
disease progression while on treatment with a first or
second-generation EGFR TKI. This study was approved
by the Ethics Committee of Liguria Region (Italy)
(P.R.273REG2016) and conducted in compliance with
the principle of the Declaration of Helsinky; a written in-
formed consent was acquired from all patients. The rele-
vant clinical characteristics of the patients are
summarized in (Additional file 1: Table S1).
Samples collection
Peripheral blood (12–18mL) was collected into
EDTA-containing tubes. Plasma was obtained by two
centrifugation rounds at 1600 x g and 3000 x g, both for
10 min at 4 °C within 2 h from collection.
Post-TKI tumor tissue was obtained from 15/42 pa-
tients undergoing biopsy for T790M analysis. The Multi-
plex I cfDNA Reference Standards at 5, 1, 0.1 and 0%
allelic frequencies (HD780, Horizon Diagnostics) mim-
icking human fragmented cfDNA (average 160 bp), were
used to evaluate the performance of Oncomine™ Lung
cfDNA Assay for sensitivity and specificity.
DNA extraction and EGFR mutations detection by Real
Time PCR
Plasma cfDNA was extracted from 3mL of plasma using
the QIAamp Circulating Nucleic Acid kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Formalin-fixed paraffin-embedded (FFPE) tumor tissue sec-
tions (5 μm thickness) were used for genomic DNA extrac-
tion with QIAamp FFPE tissue kit (Qiagen). A dedicated kit
was used for the extraction of DNA from cytological slides
according to the manufacturer’s instruction (PinPoint Slide
DNA Isolation System, Zymo Research, Euroclone, Milano,
Italy). In both tissues and cytological samples, tumor en-
richment was performed by macrodissection of areas con-
taining at least 50% of neoplastic cells.
EGFR mutations in cfDNA and tissue/cytological sam-
ples were detected with Easy EGFR Real Time PCR (Dia-
tech Pharmacogenetics, Jesi, Italy). For a limited number
of plasma samples (10/42) a Real Time PCR with a dif-
ferent chemistry was employed, PANAMutyper R EGFR
(Panagene, Bioclarma, Torino, Italy). Both the assays
were developed to achieve selective amplification of mu-
tated allele and suppression of wild type DNA. Internal
Controls (IC) were present within the PCR reactions and
amplified together with the sample to check purity and
concentration of the DNA. Then, manufacturer’s in-
structions were followed to validate each Real Time test
by checking the parameters indicated (Cycle threshold
(Ct) values of control gene amplification of DNA sam-
ples and Ct values of IC amplification).
Procedures for tag-based NGS testing
cfDNA extraction
cfDNA was isolated from 1.4–3 mL of plasma using
MagMAX™ Cell-Free DNA Isolation Kit according to
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manufacturer’s instructions (ThermoFisher Scientific,
Carlsbad, CA) and quantified using the Qubit® dsDNA
HS Assay Kit on the Qubit 3.0 fluorometer (Thermo-
Fisher). The purity and quantity of DNA size fragments
was analyzed by the Agilent High Sensitivity DNA Ana-
lysis Kit (Agilent Technologies, Santa Clara, CA, USA)
using Bioanalyzer 2100 instrument (Agilent
Technologies).
Library preparation and quantification
Targeted libraries were amplified using Oncomine™ Lung
cfDNA Assay (ThermoFisher). The assay includes 35
amplicons covering 169 key hotspot mutations in 11
genes (ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1,
MET, NRAS, PIK3CA, ROS1, and TP53) (Additional file 2:
Table S2). Patients cfDNAs (range 6–52 ng per reaction)
were employed to prepare manually targeted libraries
following manufacturer’s instructions.
Briefly, each cfDNA molecule was assigned with
unique molecular tag through a first PCR reaction in a
Veriti thermal cycler (Applied Biosystems™, Foster City,
CA) and subsequently, tagged library fragments were
amplified in a second round of PCR to produce inde-
pendent barcoded libraries. Libraries were purified using
Agencourt™ AMPure™ XP beads (Beckman Coulter, Mi-
lano, Italy).
For library quantification, a qPCR (with Ion Library
TaqMan Quantitation Kit, ThermoFisher) was performed
and run on StepOne instrument (Applied Biosystems™).
Template preparation, sequencing and data analysis
For the template preparation, 4 libraries (diluted to 50
pM) were multiplexed, and sequencing was subsequently
performed using Ion 520™ chip (5 × 106 of reads capabil-
ity), loaded on Ion Chef™ Instrument and run on Ion S5
instrument (ThermoFisher). The sequencing reads were
aligned and mapped to the reference human genome se-
quence (hg19) using the Torrent Mapping Alignment
Program (TMAP). The plugin Torrent Variant Caller
(TVC, version 5.8, ThermoFisher) with specific parame-
ters for liquid biopsy inside the JSON (JavaScript Object
Notation) file was run in order to detect and report only
the variants hotspot alleles that meet criteria for calling,
i.e. a call was made when at least two family tags shared
an identical mutation (corresponding to two independ-
ent single mutated DNA alleles) and each family tag dis-
played at least 3 reads. Optimal results were obtained
with Median Read Coverage > 25,000 and Median Mo-
lecular Coverage > 2,500 (Oncomine™ cfDNA Assays
Part III: Variant Analysis User guide).
Review of all the hotspots calls was performed by
uploading each Variant Call Format (VCF) file on IGV
(Integrative Genomics Viewer, Cambridge MA, https://
software.broadinstitute.org/software/igv/home).
Droplet digital PCR (ddPCR)
Validation of EGFR T790M mutations was performed by
QX200 ddPCR™ System (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) using ddPCR Mutation Detection
Assays (FAM-Mutation assay: dHsaCP2000019 and
HEX-wild type assay: dHsaCP2000020). For each PCR
reaction 10 ng of FFPE DNA or 5–10 μl of cfDNA ob-
tained by QIAamp (Qiagen) was amplified according to
the ddPCR mutation protocol (Oxnard et al. 2014). Each
PCR run, including samples (FFPE DNA and/or cfDNA
in 2–4 replicates to screen at least 3.000 genomes per
case) and controls (wild type, T790M-positive and no
template controls) was analyzed using QuantaSoft ana-
lytical software package (Bio-Rad Laboratories). Thresh-
old was determined according to the signals of no
template, wild-type DNA and T790M-positive control.
The allele fraction for each sample was calculated as
merged of replicates, and the positive sample was called
when at least 3 FAM-positive droplets were detected.
The limit of detection (LOD) of the ddPCR T790M
assay was initially determined and achieved values of
0.1% when at least 10 ng of DNA were analyzed. Since a
number of studies described false-positive EGFRT790M
mutation in FFPE NSCLC tumors (Ye et al., 2013; Do et
al., 2017), we set a cut-off > 0.5% by “in house” experi-
ment using 22 FFPE normal tissue samples (Add-
itional file 3: Table S3).
Statistical analysis
Statistical evaluation of the data in this study was per-
formed using GraphPad Prism version 6 software and
XLSTAT (v.19.03.44845). Threshold for statistical signifi-
cance was considered to be P < 0.05.
Results
Analytical validation of Oncomine™ Lung cfDNA assay
Sensitivity testing was initially performed starting from
30 ng cfDNA of each Multiplex I cfDNA Reference
Standard at 5, 1, 0.1 and 0% mutation frequencies and
analyzing specifically 4 different EGFR hotspots, that is
E746_A750del, L858R, T790M and V769_D770ins
(Table 1). The tag-based NGS detected all EGFR muta-
tions down to the 0.1% allele frequency with high con-
cordance between the measured allele frequencies with
those expected for each reference cfDNAs (Table 1).
Since the mutant DNA copies for L858R resulted under-
estimated compared to mutant copies found for the
other three variants (Table 1), we checked reproducibil-
ity of L858R variant call in critical samples (i.e. those
with input cfDNA < 30 ng) and tested the assay using 20
ng of the reference standard at 0.1% mutated allele fre-
quency. A positive call for the L858R mutation was
achieved with the minimum allele molecular coverage,
i.e. two molecular tags. In contrast, E746_A750del call
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was missed, although it can still be visualized on IGV
and identified by a single molecular tag. No false positive
call were observed with the test cfDNA containing wild
type EGFR gene (0% mutated allele frequency) only,
even when the VCF was visualized on IGV software.
Comparison of sensitizing and T790M EGFR mutations
detected by Real Time PCR and tag-based NGS
The plasma cfDNA from a cohort of 42 patients pro-
gressing while under TKI was tested by Real Time PCR
for EGFR mutations. The same samples were subse-
quently re-tested using Oncomine™ Lung cfDNA Assay
and the results of the two technologies compared.
Using Real Time PCR, 26/42 (61.9%) cfDNA samples
displayed the initial sensitizing EGFR mutation seen at
the diagnosis in the primary tumor and 9/42 (21.4%) also
showed a concurrent T790M mutation, whereas the
remaining cases (16/42, 38.1%) resulted negative for
both mutations (Fig. 1a, Additional file 4: Table S4).
Eight out of nine T790M-positive plasma samples by
Real Time PCR were also exon 19 deletion positive,
while only one case had a L858R co-occurring sensitiz-
ing mutation.
According to the above data, the samples with concur-
rent sensitizing EGFR mutations and the T790M substi-
tution were 9/26 (34.6%), a finding consistent with the
current reports for Real Time PCR assays (Thress et al.,
2015a; Mayo-de-las-Casas et al. 2017).
When tag-based NGS was employed on the same
cfDNA samples, the cases positive for the original sensi-
tizing EGFR mutation were 36/42 (85.7%), and those
harboring the T790M resistance mutation were 18/42
(42.85%) (Fig. 1a, Additional file 4: Table S4). All of the
latter cases also had the original sensitizing mutation;
therefore, of the 36 cases with a sensitizing mutation,
50% (18/36) also had the T790M mutation, in line with
data reported for the detection of resistance mutation in
post-TKI tissues (Yu et al. 2013; Hata et al. 2013; Sequist
et al. 2011; Oxnard et al. 2011). Among the 18
T790M-positive cases, 11 cases harbored the exon 19
deletion, 5 cases had the L858R mutation and two an
unusual EGFR mutations, i.e. one had the rare
A763_Y764insFQEA exon 20 insertion and one the
G719C exon 18 substitution (Additional file 4: Table S4).
Most of tag-based NGS-positive and Real Time
PCR-negative cases for sensitizing EGFR mutations (6/
10 cases) had the L858R mutation, leading to the con-
clusion that the coincidence rate between the two
methods was of 94% for exon 19 deletions and 57 and
40% for the L858R and uncommon EGFR mutations, re-
spectively (Fig. 1b).
No difference was observed in each patient regarding
the original EGFR sensitizing mutation between the
Table 1 Analytical testing of tag-based NGS
RS cfDNA input (ng) Library (pM) Median Read Cov Median Mol Cov EGFR gene variants VAF (%) LOD (%) Allele Mol Cov Tot Read Cov
HD780 (5%) 30 430 53,562 4365 E746_A750delELREA 5.81 0.05 265 62,561
V769_D770insASV 4.17 0.05 220 47,935
T790M 5.46 0.05 272 73,309
L858R 5.02 0.1 119 56,740
HD780 (1%) 30 408 27,829 3614 E746_A750delELREA 0.91 0.05 37 34,718
V769_D770insASV 0.85 0.05 34 23,487
T790M 0.91 0.05 40 37,057
L858R 1.15 0.1 25 29,792
HD780 (0.1%) 30 450 28,269 3778 E746_A750delELREA 0.14 0.05 6 35,994
V769_D770insASV 0.1 0.05 4 23,378
T790M 0.11 0.05 5 33,633
L858R 0.09 0.1 2 27,703
HD780 (0%) 30 570 32,314 2353 E746_A750delELREA 0 nd 0
V769_D770insASV 0 nd 0
T790M 0 nd 0
L858R 0 nd 0
HD780 (0.1%) 20 705 22,117 2734 E746_A750delELREA 0.03 0.05 1 29,492
V769_D770insASV 0.1 0.05 3 20,616
T790M 0.19 0.05 6 28,438
L858R 0.13 0.1 2 19,308
RS Reference Standard, Median Read Cov Median Read Coverage, Median Mol Cov Median Molecular Coverage, VAF Variant Allele Frequency, LOD Limit of
Detection, Allele Mol Cov Allele Molecular Coverage, Tot Read Cov Total Read Coverage, nd not detected, HD Horizon Discovery
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primary tumor tissue and the plasma samples at pro-
gression with either the Real Time PCR or the tag-based
NGS test, indicating that the specificity of both method-
ologies was 100% (Additional file 4: Table S4).
Characterization of EGFR allelic fraction detected by tag-
based NGS
Subsequently, we investigated the proportion of mutant
EGFR alleles (expressed as variant allele frequency, VAF)
a
b
Fig. 1 EGFR mutations in 42 post-TKI NSCLC patients. (a) Distribution of the various EGFR mutations types in the 42 patients according to Real
Time PCR (PCR) and tag-based NGS (NGS). The y-axis shows patients count according to different mutation patterns detected by the two
platforms. (b) Coincident Rate between Real Time PCR (grey bars) and tag-based NGS (black bars) according to the different EGFR mutations
types found. The y-axis indicated the number of cases concordant for the specific variation with both Real Time PCR and tag-based NGS and
corresponding percentages are indicated within the histogram. PCR, Real Time PCR; NGS, tag-based NGS; del, deletions; Sens, sensitizing; pos,
positive; neg, negative
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present in each patient. First of all, no relationship
was found between the whole cfDNA (range 2.8–277
pg/μl of plasma) and the mutational load assessed on
EGFR gene by tag-based NGS (Additional file 5: Fig-
ure S1). Second, when sensitizing EGFR mutations
were considered (36 cases), the VAF median percent-
age was 1.705, with a 0.06–31.3 range (Fig. 2a). In de-
tail, the VAF median value of the 10 cases that were
Real Time PCR-negative/tag-based NGS-positive for
sensitizing EGFR mutations, was significantly lower
compared to that of the 26 cases that were EGFR
positive with both methods (0.135 vs 3.68, respect-
ively; p = 0.0002 Mann-Whitney test, Fig. 2b). These
data indicate that tag-based NGS detects EGFR muta-
tions present at low-frequency in cfDNA. Third, the
majority of these low frequency EGFR mutations (6/
10, 60%), were observed among cases harboring the
L858R-type mutation (median VAF 0.105, range:
0.06–0.75). Conversely, the median VAF of cases
found L858R positive with both Real Time PCR and
tag-based NGS was definitely higher, i.e. 5.49 (Fig. 2c,
p = 0.0002, Mann-Whitney test).
Fourth, the T790M allele frequencies of the 18 positive
cases were shifted towards lower values (median VAF 0.57,
range 0.07–14.47) compared to those of EGFR mutations
(Fig. 2a and d, Del Re et al. 2017). Again, there was a statis-
tically significant difference between the median VAF value
of the 9 cases found T790M-positive by tag-based NGS
only and that of the 9 cases that resulted positive by both
technologies (0.24 and 1.74 respectively).
Orthogonal validation of T790M by ddPCR
26/42 patients (10 T790M-negative and 16 T790M-posi-
tive cases by tag-based sequencing) also were tested for
the T790M mutation by the ddPCR assay. In three cases,
classified as T790M-positive by tag-based NGS, the
ddPCR test was unsuccessful due to low cfDNA quantity
available. These were excluded from the comparative
analyses. Thirteen of the remaining 23 cases, that were
classified as T790M-positive by the tag-based NGS, were
confirmed to be positive by ddPCR with a very similar
VAF, likewise the 10 cases classified as negative by the




Fig. 2 Variant allele frequency (%) in plasma. Sensitizing EGFR mutations (n = 36 cases) and T790M mutations (n = 18 cases) were determined in
plasma by tag-based NGS and are reported as variant allele frequency percentage (%) (a) Variant allele frequency (%) for EGFR mutations
determined by tag-based NGS in two patients groups classified as positive or negative for the sensitizing mutation of EGFR based on both (black
circles) or one (black squares) the methods employed in the study (b) Results of tests similar to those in b except that the L858R and T790M
mutations were measured in (c) and (d), respectively. Each dot represents one patient. Solid lines represent median values. Statistical P values
were derived from a Mann-Whitney test. PCR, Real Time PCR; NGS, tag-based NGS; sens mut, sensitizing mutations; pos, positive; neg, negative
Dono et al. Molecular Medicine           (2019) 25:15 Page 6 of 13
Comparative analyses of EGFR mutations in plasma and
post-TKI tissues
Post-TKI specimens from 15 patients were tested for
EGFR mutations by Real Time PCR and results com-
pared with those of cfDNA testing by tag-based NGS
(Table 2).
All the post-TKI tissue specimens were positive for the
original sensitizing EGFR mutation and 5 of them dis-
played the T790M resistance mutation. When the results
obtained on tissue specimens were compared with those
of the corresponding plasma samples, 4/15 cases re-
sulted discordant (26.7%). The original sensitizing EGFR
mutation in patient 4 and the T790M resistance muta-
tion in patient 14 were not detected in plasma by
tag-based NGS, although they were both present in
post-TKI tissue specimens (Table 2). Patient 14 also re-
sulted T790M-negative by ddPCR on cfDNA. In con-
trast, the remaining discordant cases were found
T790M-positive in cfDNA and not in tissues (patients
25 and 39). In both the two post TKI tissues, absence of
T790M mutation was confirmed by ddPCR (cut-off >
0.5%; Additional file 3: Table S3). Collectively, the con-
cordance between tissue and plasma was of 93.3% for
sensitizing EGFR mutations and 80% for the T790M mu-
tation. Considering mutations found in tumor tissues as
reference values, the tag-based NGS appeared to have
80% of sensitivity and specificity for the T790M
detection in plasma, in line with other reports (Mayo--
de-las-Casas et al. 2017).
Clinical characteristics of the patients with T790M-
positive and T790M-negative cfDNA
Clinical data were available for 40/42 patients within the
cohort (Additional file 1: Table S1); among these, 18 pa-
tients resulted positive for the T790M mutation with
tag-based NGS (Additional file 4: Table S4). No signifi-
cant correlation was observed between T790M status
(positive vs. negative) and gender, ECOG (Eastern Co-
operative Oncology Group) performance status, smoking
habit, age, line of treatment in which EGFR TKI was ad-
ministered, response to EGFR TKI, or sites of disease
progression (extra-thoracic or intra-thoracic) during TKI
treatment. However, we observed that positivity for
cfDNA T790M mutation was more frequent in patients
with the exon 19 mutation than in those with the exon
21 mutation (11/18 vs 5/18, Fisher p-value: 0.046). In
addition, all T790M mutation-positive patients had re-
ceived gefitinib, whereas T790M was not found in pa-
tients treated with erlotinib or afatinib (Chi Squared
p-value: 0.013); however, this result might be influenced
by the substantial disproportion of the administered TKI
which favored gefitinib. Among the 18 T790M-positive
patients, 17 received treatment with osimertinib (80 mg/
Fig. 3 T790M detection comparison between tag-based NGS and ddPCR. Variant Allele Frequencies detected by tag-based NGS (black line) and
ddPCR (dashed line) for 23 plasma samples are shown. NGS, tag-based NGS; ddPCR, droplet digital polymerase chain reaction; VAF, Variant
Allele Frequency
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day) and were considered evaluable for clinical outcomes
(Table 3).
All but one of these were positive for the T790M mu-
tation by tag-based NGS on plasma, while in one the
mutation was observed in tissue specimen. Eight of these
17 patients also were T790M mutation positive by Real
Time PCR on plasma.
Fourteen patients were evaluable for objective re-
sponse assessment by RECIST (Response Evaluation Cri-
teria in Solid Tumors) 1.1 as their CT-scans were
Table 2 Comparison of EGFR mutational status between plasma and post-TKI tissue samples
Patient N. EGFR mutation in post-TKI Plasma EGFR mutation in post-TKI Tissues Tissue
obtained by
Tumor source
Sensitizing T790M Sensitizing T790M
2 exon 19 del pos exon 19 del pos needle biopsy pleura
18 exon 19 del pos exon 19 del pos cytology lymph node
34 exon 19 del pos exon 19 del pos needle biopsy lung
37 exon 19 del pos exon 19 del pos needle biopsy bronchus
14 exon 19 del nega exon 19 del pos cytology pleural fluid
11 L858R neg L858R neg cytology lymph node
4 neg neg L858R neg cytology liquor
13 L858R neg L858R neg cytology pleural fluid
25 L858R pos L858R neg needle biopsy lung
28 exon 20 ins neg exon 20 ins neg needle biopsy lymph node
8 L858R neg L858R neg cytology lymph node
20 L858R neg L858R neg cytology bronchus/trachea
39 G719C/S768I pos G719C/S768I neg biopsy bronchus
42 exon 19 del neg exon 19 del neg cytology vertebral bone
40 exon 19 del neg exon 19 del neg needle biopsy lung
del deletion, ins insertion, pos positive, neg negative
adiscordant EGFR results between plasma and tissues are indicated in bold letters










Real Time PCR tag-based NGS
24 M 58 exon 19 del PR pos pos
27 F 74 L858R PD pos pos
25 F 71 L858R SD neg pos
14 F 75 exon 19 del SD neg nega
35 M 64 exon 19 del PR neg pos
26 F 66 L858R PR neg pos
15 M 75 L858R SD neg pos
2 M 71 exon 19 del PR neg pos
18 F 72 exon 19 del PR pos pos
6 M 78 exon 19 del PR pos pos
10 F 71 exon 19 del PR pos pos
36 F 85 exon 19 del SD pos pos
37 F 65 exon 19 del PR pos pos
39 M 75 G719C PR pos pos
33 F 82 L858R not evaluable neg pos
16 F 66 exon 19 del SD neg pos
22 F 62 exon 20 ins SD neg pos
del deletion, PR Partial Response, PD Progressive Disease, SD Stable Disease, pos positive, neg negative
athis patient has been treated with third generation TKI because of T790M-positivity in post-TKI tissue
Dono et al. Molecular Medicine           (2019) 25:15 Page 8 of 13
available at our Institution (Table 3), while all the 17
patients were evaluable for progression-free survival
(PFS) and overall survival (OS). All the patients but
one achieved at least disease control as best re-
sponse. Among the 16 patients who were evaluable
for RECIST best objective response, nine achieved
partial response (PR, 64.28%), six stable disease (SD,
37.5%) and one patient experienced progressive dis-
ease (PD, 6.25%). The waterfall plot for objective re-
sponse of 14/16 patients is reported in
(Additional file 6: Figure S2). Most patients with
exon 19 deletions (7/9 cases) achieved objective re-
sponse with osimertinib compared to those patients
with other sensitizing mutations (1/4 cases). The
median PFS of the osimertinib-treated patients was
8.8 months and the median OS was 16.7 months.
There were no differences between patients with
exon 19 deletions and those with other mutations in
terms of PFS (8.8 vs. 8.6 months; Log Rank p-value:
0.550) or OS (18.0 vs. 16.7 months; Log Rank
p-value: 0.513). When we compared the clinical out-
come of patients receiving osimertinib according to
the results of NGS and Real Time PCR on plasma,
we observed the following results. Among the 17 pa-
tients who were T790M-positive at tag-based NGS
on plasma, eight were positive also at Real Time
PCR on plasma, while nine were negative. With
regards to RECIST response, T790M Real Time
PCR-positive patients achieved the following out-
comes: six PR, one SD, one PD; Real Time
PCR-negative patients were divided as if follows:
three PR, five SD. With regards to survival, among
the T790M tag-based NGS-positive patients receiving
osimertinib, no significant difference was observed
between Real Time PCR-positive and negative pa-
tients, both in terms of PFS (12.2 vs. 8.6 months;
Log Rank p-value: 0.177) and OS (19.2 vs. 11.6
months; Log Rank p-value: 0.143); similarly to
Fig. 4 Workflow for the identification of EGFR T790M in TKI progressed patients with advanced NSCLC. Procedures and timing of cfDNA EGFR testing
from sample arrival is represented together with the decision algorithm suggested. *Patients resulting T790M negative after NGS analysis on cfDNA
can undergone tumor biopsy, when feasible. Alternatively, the T790M negative patient can be retested on a second cfDNA after 2–4 weeks following
the National Scientific Society recommendations on liquid biopsy (https://www.aiom.it/wp-content/uploads/2018/09/2018_biopsialiquida.pdf)
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response, these data were based on a small patient
population and limited follow up.
Discussion
To date, the management of NSCLC patients progres-
sing during EGFR TKIs treatment, includes an initial at-
tempt to identify the T790M mutation in the patient’s
plasma. In the case of a negative result, a new biopsy or
fine-needle aspiration is indicated, when feasible, in
order to exclude or confirm the resistance causing muta-
tion (Normanno et al. 2017; Rolfo et al. 2018). This algo-
rithm increases the chances of detecting T790M
mutations while reducing the number of biopsies, but
may still result in delayed start of subsequent treatments
if the mutation is not detected in plasma. Therefore, any
improvement of the sensitivity of tests on cfDNA repre-
sents a relevant clinical achievement.
Since the discovery of the importance of sensitizing
EGFR mutations in the pathogenesis and treatment of
NSCLC, several different Real Time PCR assays have
been employed for the identification of EGFR mutations
in tissue. When utilized on plasma (Kim et al. 2013;
Normanno et al. 2017), it was found that, despite high
specificity, these methods were hampered by a low sensi-
tivity. The advent of NGS has opened up new perspec-
tives mostly because of its multiplexed gene approach,
although the sensitivity of this method remains challen-
ging, given that a value of 1–5% may be considered an
acceptable limit of detection. Attempts to overcome
these limits may increase the risks of false positive calls.
The technology used in this study presents several ad-
vantages compared to the classical NGS approach, since
the molecular tagging step generates single tag DNA
molecule that are amplified in a subsequent step. The al-
lelic variants will be called only if two identical molecu-
lar tags (referred to as family tags) share the same
mutation. The use of single-strand barcodes aided in re-
moving mostly late arising PCR errors as well as sequen-
cer miscalls, while maintaining an optimal sensitivity
and specificity. Our analytical tests showed that a 0.1%
sensitivity could be readily achieved with 30 ng doses of
the standard reference for all EGFR allelic variants con-
sidered and that this dose could be lowered at 20 ng
while maintaining satisfactory results (https://assets.ther-
mofisher.com/TFS-Assets/LSG/brochures/verification-
oncomine-lung-cfdna-ion-s5-white-paper.pdf).
In our study, tag-based NGS improved detection rate
for both sensitizing and, perhaps more important,
T790M resistance mutations compared to Real Time
PCR (85.7 and 42.85% versus 61.9 and 21.4%, respect-
ively). The assay was especially sensitive for L858R vari-
ation and the T790M resistance mutations that were not
detectable by the Real Time PCR and had low allele fre-
quency down to 0.06 and 0.07%, respectively.
Since the T790M mutation is usually present in
cfDNA in quantities lower than those of the sensitizing
EGFR mutations (this study and Del Re et al. 2017; Kar-
lovich et al. 2016), it is justified the need of high sensitiv-
ity tests but the disadvantage of increasing false positive
signals should be taken into account. However, in this
study, the presence of T790M in cfDNA by tag-based
NGS was an unlikely finding in the absence of a sensitiz-
ing EGFR mutation. Therefore, the testing for plasma
sensitizing EGFR mutation may serve as internal control
that informs the likelihood of falsely negative T790M re-
sults and concomitantly, provide an indirect proof for
circulating tumor derived DNA in the plasma.
Since ddPCR is known together with BEAMing PCR,
to have an high technical sensitivity (down to 0.01%), we
used it to confirm and validate our tag-based NGS for
the only T790M mutation, and interestingly, we found
equivalent sensitivity with a 100% concordance and a
similar T790M allelic frequency of the positive cases.
However, in our opinion even though the ddPCR deliver
satisfying analytical and clinical sensitivity, we believe
that the amount of cfDNA needed and the single hot-
spot detected per reaction, may be limiting factors for its
routine application.
In our study, the proportion of patients positive for
T790M mutation detected in cfDNA by tag-based NGS
was in the 50% range, consistently with data reported for
post-TKI biopsy tissues (Yu et al. 2013; Hata et al. 2013;
Sequist et al. 2011; Oxnard et al. 2011).
Although the concordance for EGFR sensitizing muta-
tions was almost complete between cfDNA and
post-TKI tissues, some discrepancy was noted for the
T790M mutation and in line with previous studies (Kim
et al. 2013; Normanno et al. 2017). Indeed, our finding is
not surprising and lack of concordance between plasma
and post-TKI tissues depends on tumor heterogeneity as
well as on specific sites of the tissue biopsy (Ilie & Hof-
man 2016). Interestingly, we found an enrichment of the
T790M mutation among cases with exon 19 deletions.
No other characteristics were correlated with the
T790M-mutated status, even the thoracic versus extra
thoracic metastatic sites, supporting that biological ra-
ther than clinical features may have a role in the devel-
opment of T790M mutation (Ke et al. 2017).
Moreover, the tag-based NGS method appears suitable
for the detection of new gene variants conferring resist-
ance to osimertinib such as the C797X mutations as well
as other mutations with similar functions (Thress et al.,
2015b). It is known that cells with EGFR C797S muta-
tion may be still sensitive to first generation TKI (and to
osimertinib) when present in trans rather than in a cis
configuration with T790M (Niederst et al. 2015; Arula-
nanda et al. 2017). In particular NGS technology com-
pared to standard methods, is able to identify both
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C797X and T790M mutations on the same amplicon
and subsequently their cis or trans configuration. In line
with this, two osimertinib treated patients (pts. 24 and
35, Additional file 4: Table S4), progressed under therapy
and the tag-based NGS detected a concurrent C797S
and C797G resistance mutations in cis configuration
(Additional file 7: Figure S3). Therefore this NGS
method may prove useful to make further therapeutic
decisions.
A limit of our study may be the relative small cohort
of patients analyzed, but our patients group is represen-
tative of a real life routine in the management of TKI
progressed NSCLC patients.
So far, despite NGS still remains a quite expensive
method, it may represent a performing test in some
diagnostic settings, such as the cfDNA analysis for
clinical therapy in advanced NSCLC (Coco et al.
2015). Indeed, firstly NGS technology is highly prefer-
able for the multiplexing ability to parallel screening
of different genes. Secondly, NGS approach compared
to standard methods, prevents the splitting of a
scarce genetic material, such as the cfDNA, in various
independent reactions thus reducing additional biases
particularly important when low mutational events
are investigated.
Lastly, the tag-based NGS technology while increasing
sensitivity and concomitantly reducing false positive
calls, provide a precise determination of the T790M al-
lelic level helping in the stratification of patients into dif-
ferent groups, that can be subsequently investigated for
their osimertinib response (Karlovich et al. 2016; Nie-
derst et al. 2015; Ariyasu et al. 2018).
Conclusions
The search of EGFR T790M mutation in ctDNA rather
than in tumor tissue DNA is becoming a reliable alter-
native procedure. However, ctDNA analysis is technically
challenging and consequently, clinical laboratories are
required to implement molecular assays in order to pro-
vide reliable and accurate EGFR test results.
In conclusion this study shows that a tag-based
NGS outperformed in ctDNA of post-TKI progressed
NSCLC patients compared to Real Time PCR, espe-
cially for detection of the resistance T790M muta-
tion. In this context, we propose an algorithm
(Fig. 4) that can be applied for the clinical manage-
ment of TKI progressed patients with advanced
NSCLC. Despite the discussed relative high cost of
methodology, in some instances tag-based NGS may
help in reducing stressful and invasive procedures.
Further larger scale studies are needed to corroborate
application of tag molecular sequencing in the search of
T790M in a clinical diagnostic context.
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